Perspectives on Enquiry & Evidence
FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?
The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.
WINTER WEEKEND READ: Role of Data Strategy in Clinical Development Success
WINTER WEEKEND READ: Tops Tips and Tricks from the Good Data Doctor
How can an optimized data strategy support your clinical program?
Does your Trial need a Synthetic Control Arm?
Why Consider a Synthetic or External Control Arm?
Webinar: Synthetic and External Controls in Clinical Trials
New Primer and Ebook on Synthetic Control Arms
Managing risk in clinical development: Is your data strategy fail-safe?
Unlock the power of your clinical data with these five top tips
Is your data strategy set up to tackle key challenges in early clinical development?
What could you accomplish with a fresh approach to your clinical data strategy?
How to optimize your data strategy to drive success in clinical development
Subscribe to our weekly newsletter
By submitting you agree to Cytel’s Privacy Notice